Criminal Prosecution of Aventis Pharmaceutical, Inc.
Aventis Pharmaceutical, Inc. ("Aventis"), a wholly-owned subsidiary of Sanofi-Aventis U.S, paid $95.5 million to resolve False Claims Act allegations that, from 1995 through 2000, it gave certain HMOs secret discounts by entering into "private label" agreements for three drugs and excluded the prices offered under those agreements from the best prices Aventis reported to the Centers for Medicare and Medicaid Services.
Aventis Pharmaceuticals, Inc., paid $180 million to resolve allegations that the company engaged in a scheme (1) to set and maintain fraudulent and inflated prices for its drug, Anzemet, knowing that federal health care programs established reimbursement rates based on those prices, and (2) to use the difference between the inflated prices reported and the actual prices charged to its customers to market, promote, and sell this drug. Aventis additionally paid $10 million to several State governments based on the same allegations.Annual Reports for FY2007 and 2010
This article was posted on July 15, 2012.